Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C43H52F2N8O6Si |
| Molecular Weight | 843.0053 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)N[C@@H](C(C)C)C(=O)N1CC(F)(F)C[C@H]1C2=NC(=CN2)C3=CC=C(C=C3)C4=CC5=C(C=C4)C6=C(C=C5)N=C(N6)[C@@H]7C[Si](C)(C)CN7C(=O)[C@@H](NC(=O)OC)C(C)C
InChI
InChIKey=IHWFCBNZRRITRU-BBACVFHCSA-N
InChI=1S/C43H52F2N8O6Si/c1-23(2)34(50-41(56)58-5)39(54)52-21-43(44,45)18-32(52)37-46-19-31(48-37)26-11-9-25(10-12-26)27-13-15-29-28(17-27)14-16-30-36(29)49-38(47-30)33-20-60(7,8)22-53(33)40(55)35(24(3)4)51-42(57)59-6/h9-17,19,23-24,32-35H,18,20-22H2,1-8H3,(H,46,48)(H,47,49)(H,50,56)(H,51,57)/t32-,33-,34-,35-/m0/s1
MK-8325 is tricyclic silyl compound patented by Schering Corporation as an antiviral agent for treating hepatitis C virus infection. MK-8325 acts as a potent hepatitis C virus nonstructural protein 5A (NS5A) inhibitor with excellent replicon activity across multiple genotypes. The compound is orally absorbed from the GI tracts of rats, dogs, and cynomolgus monkeys with low to moderate bioavailability. MK-8325 showed high protein binding in all species and is highly distributed to the target organ with minimal or no brain distribution In vitro and in vivo assays showed MK-8325 to be orally bioavailable with pharmacokinetics suitable for once-daily dosing in patients and good overall ADME profiles.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
E65594E2D0
Created by
admin on Mon Mar 31 22:05:53 GMT 2025 , Edited by admin on Mon Mar 31 22:05:53 GMT 2025
|
PRIMARY | |||
|
58426972
Created by
admin on Mon Mar 31 22:05:53 GMT 2025 , Edited by admin on Mon Mar 31 22:05:53 GMT 2025
|
PRIMARY | |||
|
1334312-52-5
Created by
admin on Mon Mar 31 22:05:53 GMT 2025 , Edited by admin on Mon Mar 31 22:05:53 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
